Company news - Shenzhen Efung Investment Management Co. Ltd.

Company news

3.5 Trillion Yuan! China's 2030 Goal for the Pharmaceutical Industry

Chinas Ministry of Industry and Information Technology, together with nine other government departments, recently issued the "15th Five-Year Plan for the Development of the Pharmaceutical Industry."The plan proposes that by 2030, Chinas biopharmaceutical R&D and application shall rank among the worlds leading positions, the effectiveness of innovation-driven development shall be fully unleashed, and systematic breakthroughs shall be achieved in key core technologies in priority fields. Core competitiveness and international influence shall rise substantially. The biopharmaceutical industry shall accelerate its transformation into a new pillar industry of the nation, continuously safeguarding and enhancing the peoples life and health.The plan sets out ten anticipated indicators, including: by 2030, the operating revenue of pharmaceutical industrial enterprises above designated size shall be no less than 3.5 trillion yuan; the proportion of first-in-class (FIC) drugs origin...

2026 - 09 - 18
Hong Kong's First Five-Year Plan Unveiled! The Healthy Greater Bay Area Ushers in a Golden Five Years | Efung Knowledge Planet

Full text: approx. 2,191 Chinese characters | Reading time: approx. 3 minutesOn September 16, John Lee, Chief Executive of the Hong Kong Special Administrative Region, announced the First Five-Year Plan for Economic and Social Development of the Hong Kong Special Administrative Region (2026–2030) (hereinafter referred to as the "Plan") at the Legislative Council meeting, and subsequently delivered his fifth Policy Address during his term.【1】This is the first five-year plan formulated since Hong Kongs return to the motherland.When explaining the relationship between the two documents, John Lee stated: The Plan is the blueprint for Hong Kongs economic and social development over the next five years, serving as a forward-looking, strategic, and directional guiding document; the Policy Address is the Chief Executives annual report on the implementation of the five-year plan, as well as the annual policy priorities and major projects in response to actual circumstances. The two ar...

2026 - 09 - 17
Efung Hardcore Sharing | From Targeting Proteins to Targeting RNA: How AI is Unlocking the Druggable Space of the Transcriptome

Modern drug discovery is built on an implicit premise: drugs act on proteins. Whether small molecules or antibodies, the essence is to find a pocket or epitope on a disease-causing protein, then bind to it and inhibit it. This paradigm has supported the pharmaceutical industry for nearly a century, and it is now approaching its ceiling—only about 1.5% of the human genome encodes proteins, of which only about ten percent are disease-related, and fewer than 700 proteins have actually been targeted by approved drugs globally to date. The vast majority of remaining disease-causing proteins—transcription factors, scaffold proteins, "undruggable" targets lacking active pockets—are beyond the reach of traditional methods. The "low-hanging fruit" has been picked clean, and protein targets are being exhausted.Since proteins are difficult to tackle, why not move upstream to the RNA that encodes them—this is a natural thought. But what truly blocks this path is an old problem ...

2026 - 09 - 15
Bridging with Capital to Forge a New Global Biotech Paradigm | Dr. Jinqiao Zhu of Evident Partners Speaks at BIOHK 2026

From September 9 to 12, 2026, the 5th Hong Kong International Biotechnology Conference and Exhibition (BIOHK 2026) was held at the Hong Kong Convention and Exhibition Centre. This year’s theme is Kaleidoscope, symbolizing a panoramic view of the industry from diverse perspectives — which mirrors the current landscape of China’s innovative drug sector: policy frameworks, capital logic and technological paradigms are all undergoing a shift. What the industry needs now is no longer a simplistic narrative, but judgment capable of weathering market cycles. Dr. Jinqiao Zhu, Founder & Chairman of Evident Partners, was invited to the summit to deliver a keynote speech and join a panel discussion.01 From “Financing Gateway” to “Pricing Hub”:Hong Kong’s Structural EvolutionAs the world’s third-largest financial centre, Hong Kong maintained robust IPO momentum in the first half of 2026, welcoming 87 new listed companies. It ranked second globally both by the number of IPOs and total capital r...

2026 - 09 - 12
Efung News | Real Biotechnology's Non-Camptothecin Toxin Debuts at CBI 2026, Breaking Through the ADC Drug Resistance Bottleneck

Recently, the CBI 2026 Biomedical Innovation Expo concluded in Suzhou, with an exhibition area of over 36,000 square meters and more than 20,000 participants gathered on site to jointly create a new industry ecosystem. The conference featured multiple parallel forums. At the ADC New Drug Discovery and Front-End Technology Innovation Forum, Dr. Dang Qun, President of Real Biotechnology, shared the companys latest achievements in overcoming ADC drug resistance with its novel non-camptothecin TOPO1 inhibitor platform.ImagePrecision therapeutic approaches represented by next-generation ADC drugs are reshaping the landscape of tumor treatment, among which TOPO1 inhibitor payloads are the most widely used clinically. However, with the widespread use of such drugs, issues of TOPO1 toxin-related target mutations and efflux pump resistance have become increasingly prominent, with cross-resistance emerging among different antibody ADCs, becoming a key bottleneck constraining efficacy improvement...

2026 - 09 - 10
Efung Knowledge Planet | 2026 National Medical Insurance Negotiations in Progress: Collectively Competing for the Medical Insurance "Admission Ticket"

The 2026 National Medical Insurance Drug Catalog Adjustmentachieves full-process parallelism with the Commercial Insurance Innovative Drug Catalog for the first time,opening up a more strategically flexible"walking on two legs" pathway.This article is approximately 2,989 words, with a reading time of about 3 minutes.On the morning of September 8, the three-and-a-half-day on-site negotiation for the National Basic Medical Insurance Catalog officially concluded. On September 9, price negotiation for the Commercial Health Insurance Innovative Drug Catalog officially launched, with final results expected to be announced in late November.Just one day before the negotiations began, the State Council Information Office held a press conference in the "Starting the 15th Five-Year Plan" series, at which Li Tao, Deputy Director and Spokesperson of the National Healthcare Security Administration, introduced arrangements related to medical insurance reform and development, pharm...

2026 - 09 - 09

Copyright © 2018 2021.All Rights Reserved 粤公网安备44030402002338号 Rhino Cloud provides enterprise cloud services 犀牛云提供云计算服务